MEA Technetium 99m Market, By Isotopic Application (Gamma Camera and SPECT), By End User (Hospitals and Diagnostic Center), and By country (Saudi Arabia, Algeria, Bahrain, Cyprus, Egypt, Iran, Iraq, Israel, Jordan, Kuwait, Lebanon, Libya, Morocco, Mauritania, Oman, Palestine, Qatar, Syria, Tunisia, Turkey and Yemen)

Published In : Jul 2023

Code : CMI3874

Pages :154

Formats :

Excel and PDF

Industry : Pharmaceutical

Market News

MEA Technetium 99m Market: Key Developments

In March 2020, Navidea Biopharmaceuticals, Inc., one of the leaders in precision medicine with immuno-targeted products, received the U.S. Patent extension for Lymphoseek (technetium [Tc 99m] tilmanocept), a radioactive diagnostic agent which accumulates in lymphatic tissue and selectively binds to mannose-binding receptors (CD206) located on the surface of macrophages and dendritic cells, until 2025.

In 2020, the UAE's Abu Dhabi Health Services Company (SEHA), a healthcare network established a centralized radiopharmacy facility, which included Technetium 99m production capabilities. The facility aimed to ensure the availability of radiopharmaceuticals, including Technetium 99m, for healthcare facilities across the UAE.

In February 2020, BWX Technologies, Inc., one of the leading suppliers of nuclear components and fuel successfully labeled technetium-99m derived from its proprietary molybdenum-99 production process and its proprietary Tc-99m generators with cold kits.

In November 2019, researchers from the Institute of Nuclear and Radiological Sciences and Technology, Greece, reported the synthesis and characterization of two novel derivatives of undecanonoic and hexadecanonoic acid with the aim of developing 99mTc-labeled fatty acids intended for myocardial metabolism imaging.